ClinicalTrials.gg
RecruitingNCT07628660FSFI-ENDOUpdated Jun 5, 2026

Assessment of Female Sexual Function Index (FSFI) Scores at 1 Month After Endometrial Sampling Performed Under Sedo-Analgesia or Local Anesthesia

An observational study in Female Sexual Dysfunction, Endometrial Sampling and Female Sexual Function Index (FSFI), sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

Endometrial sampling is a commonly performed gynecological procedure used for the diagnosis of abnormal uterine bleeding and endometrial abnormalities. Different anesthetic techniques may be used during the procedure, including sedo-analgesia and local anesthesia.

The purpose of this prospective observational study is to evaluate whether the anesthetic technique used during endometrial sampling affects female sexual function one month after the procedure. Female sexual function will be assessed using the validated Female Sexual Function Index (FSFI) questionnaire.

A total of 210 women undergoing endometrial sampling at Prof. Dr. Cemil Taşcıoğlu City Hospital will be enrolled. Participants will be assigned to groups according to the anesthetic technique used during their routine clinical care. FSFI scores obtained at the one-month follow-up visit will be compared between women who underwent the procedure under sedo-analgesia and those who received local anesthesia.

Secondary analyses will include comparison of FSFI scores according to symptom status and histopathological diagnosis.

The findings of this study may contribute to a better understanding of the impact of anesthetic techniques on postoperative sexual health and quality of life in women undergoing gynecological procedures.

Read the detailed description

Endometrial sampling is a widely used gynecological procedure for the diagnosis and management of abnormal uterine bleeding and suspected endometrial pathology. The procedure may be performed under different anesthetic techniques, including sedo-analgesia and local anesthesia. Sedo-analgesia provides patient comfort through the administration of short-acting sedative and analgesic agents, whereas local anesthesia reduces procedural pain by blocking cervical nerve transmission. Both techniques are routinely used in clinical practice.

Sexual health is an important component of physical and psychological well-being. Procedure-related pain, anxiety, and postoperative discomfort may influence female sexual function and quality of life. However, limited data are available regarding the potential impact of anesthetic technique during endometrial sampling on subsequent sexual function.

The aim of this prospective observational cohort study is to evaluate whether undergoing endometrial sampling under sedo-analgesia or local anesthesia affects Female Sexual Function Index (FSFI) scores at one month after the procedure.

The study will be conducted at the Department of Obstetrics and Gynecology, Prof. Dr. Cemil Taşcıoğlu City Hospital, between April 2026 and April 2027. A total of 210 women aged 18 to 60 years undergoing endometrial sampling will be enrolled. Participants will be allocated into two cohorts according to the anesthetic technique used during routine clinical care:

Sedo-analgesia group (n=105) Local anesthesia group (n=105) Female sexual function will be evaluated at the one-month follow-up visit using the validated Female Sexual Function Index (FSFI), a 19-item questionnaire assessing six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain.

Demographic and clinical characteristics, including age, gravidity, parity, and abortion history, will also be recorded. FSFI scores will be compared between the two groups to determine whether anesthetic technique is associated with differences in postoperative sexual function.

Secondary analyses will include comparison of FSFI scores according to symptom status and histopathological diagnosis.

The results of this study may provide evidence regarding the influence of anesthetic management during gynecological procedures on female sexual health and may contribute to improving patient-centered perioperative care.

02

Conditions studied

  • Female Sexual Dysfunction
  • Endometrial Sampling
  • Female Sexual Function Index (FSFI)
  • Abnormal Uterine Bleeding, Unspecified

Browse trials for

Keywords

  • Endometrial Sampling,Female Sexual Function Index,Sedo-Analgesia,Local Anesthesia,Abnormal Uterine Bleeding,Sexual Health
03

In context

Metrorrhagia

153 studies on the registry are indexed under Metrorrhagia; 34 are open to participants now.

This study's planned enrollment of 210 is above the median of 171 across 33 observational studies indexed under Metrorrhagia.

Browse Metrorrhagia studies →

Lead sponsor

Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization is the lead sponsor of 87 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of women aged 18-60 years undergoing endometrial sampling for various gynecological indications at the Department of Obstetrics and Gynecology, Prof. Dr. Cemil Taşcıoğlu City Hospital. Participants receiving sedo-analgesia or local anesthesia as part of routine clinical care will be included. Female sexual function will be assessed one month after the procedure using the Female Sexual Function Index (FSFI), and subgroup analyses may be performed according to symptom status and histopathological diagnosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 60 years
  • Undergoing endometrial sampling at the Department of Obstetrics and Gynecology, Prof. Dr. Cemil Taşcıoğlu City Hospital
  • Undergoing the procedure under sedo-analgesia or local anesthesia as part of routine clinical practice
  • Attendance at the 1-month follow-up visit
  • Ability to complete the Female Sexual Function Index (FSFI) questionnaire

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years or older than 60 years
  • Presence of known chronic systemic disease
  • Incomplete clinical or follow-up data
  • Failure to attend the 1-month follow-up visit
  • Inability or unwillingness to complete the FSFI questionnaire
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sedo-Analgesia Group

    Patients undergoing endometrial sampling under intravenous sedo-analgesia as part of routine clinical care.

  • Local Anesthesia Group

    Patients undergoing endometrial sampling under local anesthesia as part of routine clinical care.

06

What researchers measure

Primary outcomes

  1. Female Sexual Function Index (FSFI) Score at 1 Month

    Assessment of female sexual function one month after endometrial sampling using the validated Female Sexual Function Index (FSFI) questionnaire. Total FSFI scores will be compared between patients undergoing endometrial sampling under sedo-analgesia and those undergoing the procedure under local anesthesia.

    Time frame: 1 Month After Endometrial Sampling

Secondary outcomes

  1. FSFI Subdomain Scores at 1 Month

    Assessment of FSFI subdomain scores, including desire, arousal, lubrication, orgasm, satisfaction, and pain, one month after endometrial sampling.

    Time frame: 1 Month After Endometrial Sampling

Other outcomes

  1. FSFI Scores According to Histopathological Diagnosis

    Comparison of total FSFI scores between patients with benign and malignant histopathological results after endometrial sampling.

    Time frame: 1 Month After Endometrial Sampling

  2. FSFI Scores According to Symptom Status

    Comparison of total FSFI scores between symptomatic and asymptomatic patients undergoing endometrial sampling.

    Time frame: 1 Month After Endometrial Sampling

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant confidentiality and in accordance with institutional and ethical regulations governing clinical research data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Apr 15, 2026
Primary completionEst.
May 15, 2027
CompletionEst.
May 15, 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07628660
Lead sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Responsible party
Yağmur ÖZKAN (M.D., Department of Obstetrics and Gynecology, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization) — Principal investigator
First posted
Jun 5, 2026
Start date
Apr 15, 2026
Primary completion
May 15, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Yağmur ÖZKAN, M.D.
Contact
yagmurolmez92@hotmail.com
+90 5374318241

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion